Trends in nephropathy among HIV-infected patients

Journal of the National Medical Association

Volumn 101, Issue 12, 2009, Pages 1205-1213

  Buskin, Susan E ^a,b   Torno, Mauro S ^c,d   Talkington, Deborah F ^e,f   Zhang, Ming ^f,g   Jones, Jeffrey L ^h   Butler, Jay C ^f,i   McNaghten, A D ^h   Dworkin, Mark S ^h,j,k  

^a PUBLIC HEALTH SEATTLE AND KING COUNTY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

^e NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^f NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^g NATIONAL CENTER FOR ENVIRONMENTAL HEALTH   (United States)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

ⁱ Alaska Division of Public Health   (United States)

^j ILLINOIS DEPARTMENT OF PUBLIC HEALTH   (United States)

^k UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

more..

Author keywords

HIV AIDS; Kidney

Indexed keywords

CREATININE; INDINAVIR; RITONAVIR;

ADOLESCENT; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH DISPARITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MORTALITY; NEGRO; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; TIME OF DEATH; TREND STUDY; VIRUS LOAD;

EID: 75149193439     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)31131-7     Document Type: Article

References (32)

1. Ahuja TS, Borucki M, Funtanilla M, et al. Is the prevalence of HlV-associated nephropathy decreasing? Am J Nephrol. 1999;19:655-659.
2. Rao TK, Filippone EJ, Nicastri AD, et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med. 1984;310:669-673.
3. Bourgoignie JJ, Ortiz-lnterian C, Green DF, et al. Race, a cofactor in HIV-1-associated nephropathy. Transplant Proc. 1989;21:3899-3901.
4. Kimmel PL, Phillips TM, Ferreira-Centeno A, et at. HIV-associated immune-mediated renal disease. Kidney Int. 1993;44:1327-1340.
5. Laradi A, Mallet A, Beaufils H, et al. HIV-associated nephropathy: outcome and prognosis factors. Groupe d' Etudes Nephrologiques d'Ile de France. J Am Soc Nephrol. 1998;9:2327-2335.
6. Abbott KC, Hypolite I, Welch PG, et al. Human immunodeficiency virus/ acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretrovral therapy era. J Nephrol. 2001;14:377-383.
7. Lucas GM, Eustace JA, Sozio S, et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS. 2004;18:541-546.
8. U.S. Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2003:47-60. http://www.usrds.org/adr-2003.htm. Accessed November 17, 2008.
9. Röling J, Schmid H, Fischereder M, et al. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis. 2006;42:1488-1495.
10. Farizo KM, Buehler JW, Chamberland ME, et al. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA. 1992;267:1798-1805.
11. Chu SY, Hanson DL, Jones JL, Adult/adolescent HIV Spectrum of Disease Project Group. Pregnancy rates among women infected with the human immunodeficiency virus. Obstet Gynecol. 1996;87:195-198.
12. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1-19.
13. Levey AS, Greene T, Kusek JW, and Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine (abstract A0828). J Am Soc Nephrol. 2000;11:155A.
14. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1-S266.
15. Dieleman JP, Sturkenboom MC, Jambroes M, et al. Risk factors for uro-logical symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort. Arch Intern Med. 2002;162:1493-1501.
16. Gulick RM, Mellors JW, Havlir D, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med. 2000;133:35-39.
17. Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med. 1997;127:119-125.
18. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559-1585.
19. Dworkin MS, Wan PC. Indinavir, zidovudine, lamivudine: 3-year follow-up (letter). Ann Intern Med. 2001;134:165.
20. D'Agati V, Appel GB. HIV infection and the kidney. J Am Soc Nephrol. 1997;8:139-152.
21. Kimmel PL, Barisoni L, Kopp JB. Pathogenesis and treatment of HIV-associated renal diseases: Lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann Intern Med. 2003;139:214-226.
22. Kalayjian RC, Franceschini N, Gupta SK, et al. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS. 2008;22:481-487.
23. Reid A, Stohr W, Walker AS, et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis. 2008;46:1271-1281.
24. Lucas GM, Lau B, Atta MG, et al. Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis. 2008;197:1548-1557.
25. Ahuja TS, Grady J, Khan S. Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States. J Am Soc Nephrol. 2002;13:1889-1893.
26. Ferguson R, Morrissey E. Risk factors for end-stage renal disease among minorities. Transplant Proc. 1993;25:2415-2420.
27. Rodriguez RA, Mendelson M, O'Hare AM, et al. Determinants of survival among HIV-infected chronic dialysis patients. J Am Soc Nephrol. 2003;14:1307-1313.
28. Galai N, Safaeian M, Vlahov D, et al. Longitudinal Patterns of Drug Injection Behavior in the ALIVE Study Cohort, 1988-2000: Description and Determinants. Am J Epidemiol. 2003;158:695-704.
29. Giordano TP, Morgan RO, Kramer JR, et al. Is There a Race-based Disparity in the Survival of Veterans with HIV? J Gen lnfern Med. 2006;21:613-616.
30. Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008;40(10):1175-1184.
31. Nuermberger E. Nephropathy, HIV-Associated (HIVAN). In Barttett JG, Gallant JE, Pham P, eds. 2007 Medical Management of HIV Infection. Baltimore: Johns Hopkins University Division of Infectious Diseases; 2007. http://www.hopkins-hivguide.org/. Accessed November 17, 2008.
32. Estrada AL. Health disparities among African-American and Hispanic drug injectors - HIV, AIDS, hepatitis B virus and hepatitis C virus: a review. AIDS. 2005;suppl 3:S47-S52. ■